Our founders, advisors and team have extensive women's health product development experience and are uniquely qualified to deliver this much needed product.
Seasoned Core Team
Valerie Ceva
Strategic/Launch Operations Advisor; Board
COO BioAegis Therapeutics, Formerly Novartis Life science management in Pharma & Emerging Growth: Marketing & Venture.
Susan L. Levinson, Ph.D.
Strategic/Launch Operations Advisor; Board
CEO BioAegis Therapeutics Pharma strategic operational experience: R&D, Licensing; Formerly Novartis.
Steven R. Goldstein, MD
Chair, Clinical Advisory Board
Professor of Obstetrics and Gynecology NYU Grossman School of Medicine; Past President of the North American Menopause Society (NAMS); President Elect of the International Menopause Society; Pfizer’s lasofoxifene KOL.
David D. Thompson, Ph.D.
Founder/Scientific Lead
Former Global Head Pfizer’s lasofoxifene team Former VP and Global Team Leader for Alexion Pharmaceuticals’ Strensiq.
Chris Cimarusti, Ph.D.
Manufacturing Lead
Former SVP Manufacturing, Bristol-Myers Squibb Responsible for all CMC disciplines including GMP compliance.
Ginger D. Constantine, MD
Clinical Strategy Lead
Formerly VP Women’s Health, Wyeth Responsible for clinical trial and regulatory strategy and operations.
World Class Clinical Advisory Board
Steven R. Goldstein, MD
Chair, Clinical Advisory Board
Professor of Obstetrics and Gynecology NYU Grossman School of Medicine; Past President of the North American Menopause Society (NAMS); President Elect of the International Menopause Society; Pfizer’s lasofoxifene KOL.
Risa Kagan, MD
Clinical Advisor
Professor of Obstetrics and Gynecology University of California, San Francisco Trustee, North American Menopause Society
Lila Nachtigall, MD
Clinical Advisor
Professor of Obstetrics and Gynecology NYU Grossman School of Medicine; Past President, North American Menopause Society
James A. Simon, MD
Clinical Advisor
Clinical Professor of Obstetrics and Gynecology George Washington University Past President, North American Menopause Society
Ginger Constantine, MD
Clinical Strategy Lead
Formerly VP Women’s Health, Wyeth clinical trial and regulatory strategy and operations; Premarin, Imvexxy, Osphena, others
Lisa Rarick, MD
Regulatory Strategy
15 yrs with FDA, including as Division Director, Reproductive and Urologic Products. Board certified Obstetrician/Gynecologist.